How India Exports Amiodarone to the World

In the United States, amiodarone has been approved through multiple Abbreviated New Drug Applications (ANDAs). Notably, Upsher-Smith Laboratories, Inc. received approval for its generic version of amiodarone hydrochloride tablets (ANDA 75-135) on April 30, 1998. Similarly, Copley Pharmaceutical, Inc. secured approval for its formulation (ANDA 74-739) on November 30, 1998, and Par Pharmaceutical, Inc. followed with approval (ANDA 75-188) on February 24, 1999.

The FDA's regulatory pathway for amiodarone involves stringent evaluation of bioequivalence and manufacturing standards to ensure safety and efficacy. Given the substantial number of Indian exporters involved in supplying amiodarone to the U.S. market, compliance with FDA regulations, including Good Manufacturing Practices (GMP) and periodic inspections, is imperative to maintain market access.

In the European Union, the European Medicines Agency (EMA) oversees the marketing authorization of medicinal products, including amiodarone. The authorization process requires comprehensive data on quality, safety, and efficacy. Manufacturers must adhere to the EU's Good Manufacturing Practice (GMP) guidelines, ensuring consistent product quality.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicinal products. Post-Brexit, the UK has established its own regulatory framework, though it remains aligned with EU standards in many aspects. Manufacturers exporting amiodarone to the UK must comply with MHRA's requirements, including obtaining marketing authorization and adhering to GMP standards.

Amiodarone is listed in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in treating priority health conditions. The 2025 edition of the WHO Model List includes over 520 medicines, reflecting the organization's commitment to ensuring access to essential treatments. (who.int)

Regarding pharmacopoeial standards, amiodarone is included in major compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards provide specifications for the drug's quality, ensuring consistency across different markets.

In India, amiodarone is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. This classification mandates that amiodarone can only be sold by retail pharmacies upon the prescription of a registered medical practitioner.

The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines in India. As of the latest available data, amiodarone is subject to price control measures to ensure affordability. Manufacturers intending to export amiodarone must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

The primary patents for amiodarone have expired, leading to the availability of multiple generic versions in the market. This expiration has facilitated increased competition among manufacturers, contributing to the widespread availability and affordability of the drug globally.

In May 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of amiodarone, highlighting its continued importance in global health. (who.int)

In January 2026, the FDA issued updated guidance on the manufacturing standards for antiarrhythmic drugs, including amiodarone, emphasizing the need for enhanced quality control measures to ensure patient safety.

In March 2026, the NPPA revised the ceiling price for amiodarone under the DPCO, reflecting changes in production costs and market dynamics to maintain affordability for patients.

These developments underscore the dynamic regulatory environment surrounding amiodarone, necessitating continuous monitoring by stakeholders to ensure compliance and market competitiveness.

India's pharmaceutical industry, including the production of Amiodarone, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. According to the US Pharmacopeia, 58% of KSMs used for U.S.-approved APIs are sourced from a single country, predominantly China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

Recent events have exacerbated these vulnerabilities. In March 2026, escalating conflicts in the Middle East, particularly the closure of the Strait of Hormuz, have disrupted global shipping routes. This has led to significant delays and increased costs in transporting raw materials, including KSMs, from China to India. The United Nations Conference on Trade and Development (UNCTAD) highlighted that the Strait carries around one-quarter of global seaborne oil trade, as well as significant volumes of liquefied natural gas and fertilizers, and its disruption has raised concerns about ripple effects across global markets.

Our proprietary trade data indicates a high concentration in Amiodarone exports from India, with the top five exporters accounting for 90.3% of the total export value. UNICHEM LABORATORIES LIMITED alone holds a 49.8% share, amounting to $37.2 million USD. This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could severely disrupt the global supply of Amiodarone.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce dependency on imports. However, the effectiveness of this initiative in diversifying the supplier base for Amiodarone remains to be seen, as the scheme's impact is still unfolding.

The ongoing conflict in the Middle East has led to the effective closure of the Strait of Hormuz since February 28, 2026, following joint military strikes by the United States and Israel on Iran. This has caused a sharp decline in maritime transit, with tanker traffic dropping by approximately 70% initially and eventually to near zero. This disruption has affected about 20% of the world's daily oil supply and significant volumes of liquefied natural gas (LNG), prompting major shipping firms to suspend operations in the area.

These disruptions have led to increased shipping costs and delays, impacting the timely delivery of pharmaceuticals, including Amiodarone. The UNCTAD has noted that military escalation in the region has disrupted shipping flows, raising concerns about ripple effects across energy markets, maritime transport, and global supply chains.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different geographic regions to reduce dependency on a single country.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical APIs and KSMs to strengthen supply chain resilience.

• Strengthen Supplier Relationships: Establish long-term contracts and collaborative partnerships with multiple suppliers to ensure a stable supply chain.

• Monitor Geopolitical Developments: Implement a robust monitoring system to stay informed about geopolitical events that could impact supply chains and develop contingency plans accordingly.

• Optimize Inventory Management: Maintain strategic stockpiles of critical pharmaceuticals to buffer against supply disruptions.

RISK_LEVEL: HIGH